Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Profit After Tax (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Profit After Tax for 11 consecutive years, with -$2.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Profit After Tax rose 13.41% to -$2.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$14.3 million, a 48.42% decrease, with the full-year FY2024 number at -$10.7 million, up 23.6% from a year prior.
  • Profit After Tax was -$2.0 million for Q3 2025 at Marker Therapeutics, up from -$4.0 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $2.5 million in Q2 2023 to a low of -$12.4 million in Q3 2021.
  • A 5-year average of -$4.8 million and a median of -$3.8 million in 2024 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: skyrocketed 329.68% in 2023, then crashed 187.16% in 2024.
  • Marker Therapeutics' Profit After Tax stood at -$9.8 million in 2021, then skyrocketed by 68.83% to -$3.0 million in 2022, then grew by 9.96% to -$2.7 million in 2023, then tumbled by 40.05% to -$3.8 million in 2024, then soared by 47.92% to -$2.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Profit After Tax are -$2.0 million (Q3 2025), -$4.0 million (Q2 2025), and -$4.4 million (Q1 2025).